IBDEI36O ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,50830,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50830,1,3,0)
 ;;=3^Personal Hx of Leukemia
 ;;^UTILITY(U,$J,358.3,50830,1,4,0)
 ;;=4^Z85.6
 ;;^UTILITY(U,$J,358.3,50830,2)
 ;;=^5063434
 ;;^UTILITY(U,$J,358.3,50831,0)
 ;;=Z85.72^^193^2498^98
 ;;^UTILITY(U,$J,358.3,50831,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50831,1,3,0)
 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
 ;;^UTILITY(U,$J,358.3,50831,1,4,0)
 ;;=4^Z85.72
 ;;^UTILITY(U,$J,358.3,50831,2)
 ;;=^5063436
 ;;^UTILITY(U,$J,358.3,50832,0)
 ;;=Z85.79^^193^2498^88
 ;;^UTILITY(U,$J,358.3,50832,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50832,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,50832,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,50832,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,50833,0)
 ;;=Z85.820^^193^2498^77
 ;;^UTILITY(U,$J,358.3,50833,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50833,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,50833,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,50833,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,50834,0)
 ;;=Z85.828^^193^2498^92
 ;;^UTILITY(U,$J,358.3,50834,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50834,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,50834,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,50834,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,50835,0)
 ;;=Z85.71^^193^2498^72
 ;;^UTILITY(U,$J,358.3,50835,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50835,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,50835,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,50835,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,50836,0)
 ;;=Z65.8^^193^2498^144
 ;;^UTILITY(U,$J,358.3,50836,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50836,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,50836,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,50836,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,50837,0)
 ;;=Z86.11^^193^2498^109
 ;;^UTILITY(U,$J,358.3,50837,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50837,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,50837,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,50837,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,50838,0)
 ;;=Z86.13^^193^2498^76
 ;;^UTILITY(U,$J,358.3,50838,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50838,1,3,0)
 ;;=3^Personal Hx of Malaria
 ;;^UTILITY(U,$J,358.3,50838,1,4,0)
 ;;=4^Z86.13
 ;;^UTILITY(U,$J,358.3,50838,2)
 ;;=^5063463
 ;;^UTILITY(U,$J,358.3,50839,0)
 ;;=Z86.73^^193^2498^106
 ;;^UTILITY(U,$J,358.3,50839,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50839,1,3,0)
 ;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
 ;;^UTILITY(U,$J,358.3,50839,1,4,0)
 ;;=4^Z86.73
 ;;^UTILITY(U,$J,358.3,50839,2)
 ;;=^5063477
 ;;^UTILITY(U,$J,358.3,50840,0)
 ;;=Z86.79^^193^2498^69
 ;;^UTILITY(U,$J,358.3,50840,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50840,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
 ;;^UTILITY(U,$J,358.3,50840,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,50840,2)
 ;;=^5063479
 ;;^UTILITY(U,$J,358.3,50841,0)
 ;;=Z91.040^^193^2498^57
 ;;^UTILITY(U,$J,358.3,50841,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50841,1,3,0)
 ;;=3^Latex Allergy Status
 ;;^UTILITY(U,$J,358.3,50841,1,4,0)
 ;;=4^Z91.040
 ;;^UTILITY(U,$J,358.3,50841,2)
 ;;=^5063607
 ;;^UTILITY(U,$J,358.3,50842,0)
 ;;=Z92.3^^193^2498^73
